<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T10:23:50Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/110400" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/110400</identifier><datestamp>2026-05-15T19:42:11Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Fu, Jingxin</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair">DeLisa, Matthew</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Alabi, Christopher Akinleye</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2021-12-20T20:34:26Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2021-12-20T20:34:26Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2021-08</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 11236</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 28649292</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/110400</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/ekaw-na06</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">15160283</dim:field>
   <dim:field mdschema="dc" element="description">81 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Antibody-based immunotherapy is one of the most significant medical advancement of the 21st century. Monoclonal antibodies (mAb) and their conjugation variants are found to be effective in treating a myriad of conditions including autoimmune and cancer diseases. mAb is a complex biomolecule consisting of multiple polypeptides and post-translational modifications including disulfide bond and N-linked protein glycosylation. Such complexity contributes to a challenge in biomanufacturing, quality assessment, and storage of the mAb, which leads to a high cost of antibody therapy. Hence one of the major objectives of the mAb engineering is to increase its circulating half-life which will help to both reduce therapy cost and improve health care quality. In this work, we proposed using a cell-free glycoengineering strategy to enhance therapeutic antibody half-life. We employed engineered sialyltransferases derived from Campylobacter jejuni and Neisseria meningitidis to extend IgG-Fc N-glycans at the non-reducing end with the polysialic acid polymer. Using our optimized one-pot two-stage biosynthesis protocol, therapeutic antibody Herceptin modified with polysialic acid structure was efficiently produced and structurally validated. The ongoing works including a more extensive structural characterization as well as ex vivo functional assays will be discussed. Taken together, we anticipate cell-free glycoengineering technology producing polysialylated IgG will provide an attractive route for producing therapeutic mAb with enhanced stability and circulating half-life.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="subject">antibody half-life</dim:field>
   <dim:field mdschema="dc" element="subject">cell-free glycoengineering</dim:field>
   <dim:field mdschema="dc" element="subject">glycosylation</dim:field>
   <dim:field mdschema="dc" element="subject">polysialylation</dim:field>
   <dim:field mdschema="dc" element="title">IN VITRO ENZYMATIC POLYSIALYLATION OF THERAPEUTIC ANTIBODIES USING ENGINEERED GLYCOSYLTRANSFERASES</dim:field>
   <dim:field mdschema="dc" element="type">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/15160283</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Master of Science</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">M.S., Chemical Engineering</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Fu, Jingxin</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="a8829d0c-f8d5-48c7-9e06-3850a347ac62">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>IN VITRO ENZYMATIC POLYSIALYLATION OF THERAPEUTIC ANTIBODIES USING ENGINEERED GLYCOSYLTRANSFERASES&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2021-08&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/ekaw-na06&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Fu, Jingxin&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;Keyword>antibody half-life&lt;/Keyword>
    &lt;Keyword>cell-free glycoengineering&lt;/Keyword>
    &lt;Keyword>glycosylation&lt;/Keyword>
    &lt;Keyword>polysialylation&lt;/Keyword>
   	&lt;Abstract>Antibody-based immunotherapy is one of the most significant medical advancement of the 21st century. Monoclonal antibodies (mAb) and their conjugation variants are found to be effective in treating a myriad of conditions including autoimmune and cancer diseases. mAb is a complex biomolecule consisting of multiple polypeptides and post-translational modifications including disulfide bond and N-linked protein glycosylation. Such complexity contributes to a challenge in biomanufacturing, quality assessment, and storage of the mAb, which leads to a high cost of antibody therapy. Hence one of the major objectives of the mAb engineering is to increase its circulating half-life which will help to both reduce therapy cost and improve health care quality. In this work, we proposed using a cell-free glycoengineering strategy to enhance therapeutic antibody half-life. We employed engineered sialyltransferases derived from Campylobacter jejuni and Neisseria meningitidis to extend IgG-Fc N-glycans at the non-reducing end with the polysialic acid polymer. Using our optimized one-pot two-stage biosynthesis protocol, therapeutic antibody Herceptin modified with polysialic acid structure was efficiently produced and structurally validated. The ongoing works including a more extensive structural characterization as well as ex vivo functional assays will be discussed. Taken together, we anticipate cell-free glycoengineering technology producing polysialylated IgG will provide an attractive route for producing therapeutic mAb with enhanced stability and circulating half-life.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>